Daphne Koller on Why Insitro Skipped Biotech’s Shortcut |
Business Finance Media Technology Policy Wealth Insights Interviews
Art Art Fairs Art Market Art Reviews Auctions Galleries Museums Interviews
Lifestyle Nightlife & Dining Style Travel Interviews
Power Lists Nightlife & Dining Art A.I. PR
About About Observer Advertise With Us Reprints
Daphne Koller on Why Insitro Skipped Biotech’s Shortcut
Most A.I. drug-discovery startups solve the same early problem the same way: license in a molecule that never came off their own platform, so investors have something to point to while the real engine still finds its legs. Daphne Koller refused. Now Bristol Myers Squibb and Eli Lilly are paying to find out if patience was the better trade.
Daphne Koller does not like the phrase “move fast and break things.” She says so almost immediately, and she says it the way people say things they’ve been asked before and have long since stopped softening. “Living in a sector where the products that we produce are drugs that have to go into a person, the notion of ‘break things’ is a very bad idea,” Koller tells Observer. “You do not want to break things when you’re going into a clinical trial and cause risk to your patients.”
Sign Up For Our Daily Newsletter
Thank you for signing up!
By clicking submit, you agree to our terms of service and acknowledge we may use your information to send you emails, product samples, and promotions on this website and other properties. You can opt out anytime.
It is an obvious point. Coming from Koller, it is also a rejection of the operating philosophy that built the industry she has spent the last eight years trying to out-execute. Koller trained as a Bayesian statistician, taught computer science at Stanford for 20 years, and won a MacArthur “genius” grant in 2004 for work bridging logic and probability before co-founding Coursera, the online education company she left at a valuation of roughly $1 billion. In 2018, Koller started over, founding Insitro on the premise that drug discovery—an industry famous for burning a decade and a billion dollars per approved therapy—could be re-engineered, as she’d once tried to re-engineer the university lecture. She has since built a company backed by more than $750 million in capital, including roughly $140 million in pharma collaboration revenue, toward turning algorithmic target discovery into clinical candidates.
Insitro raised its first $100 million in six months, from ARCH Venture Partners, Andreessen Horowitz, Foresite Capital, Alphabet’s GV and Third Rock, with Jeff Bezos joining later. Within a year, Koller had a deal with Gilead worth $15 million upfront against roughly $1 billion in potential milestones, for work on fatty liver disease. Seven years later, Insitro is running two live programs—one in ALS with Bristol Myers Squibb, one in metabolic disease with Eli Lilly—both tracing back to targets Koller’s platform surfaced from human genetics, not from a chemist’s hunch.
The Bristol Myers Squibb partnership is the clearest evidence that the model is compounding. BMS paid to expand its collaboration with Insitro twice in the past year: $20 million in October 2025 to extend work on an Insitro-discovered ALS target, then $10 million in March 2026 when BMS nominated two additional targets sourced from Insitro’s Virtual Human platform—bringing the portfolio to three ALS targets and more than $2 billion in potential milestones plus royalties. Separately, in September 2025, Eli Lilly signed on to train machine-learning models on its own proprietary preclinical data, a bet that Insitro’s modeling can shrink the animal-study cycles required before a candidate is chosen.
Following its January acquisition of the Israeli biologics-design startup CombinAbleAI—folded into a new platform Insitro calls TherML, built to extend the company’s target-discovery engine into molecule design and manufacturability across small molecules, oligonucleotides and antibodies—Insitro’s lead candidate has moved from genetics to mice. CTRO-1013, an A.I.-discovered siRNA therapy that silences the gene IRS1 to treat MASH, the metabolic liver........